159 related articles for article (PubMed ID: 16328600)
1. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein.
Rebischung C; Barnoud R; Stéfani L; Faucheron JL; Mousseau M
Gastric Cancer; 2005; 8(4):249-52. PubMed ID: 16328600
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
3. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
Sbitti Y; Essaidi I; Debbagh A; Kadiri H; Oukabli M; Moussaid Y; Slimani K; Fetohi M; Elkaoui H; Albouzidi A; Mahi M; Ali AA; Ichou M; Errihani H
World J Surg Oncol; 2011 Sep; 9():112. PubMed ID: 21955806
[TBL] [Abstract][Full Text] [Related]
4. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
Dong CX; Fu JF; Ye XY; Li XF; Zhong X; Yuan Y
World J Gastroenterol; 2014 Sep; 20(34):12355-8. PubMed ID: 25232273
[TBL] [Abstract][Full Text] [Related]
5. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
6. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
7. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE; Hozaeel W; Jäger E
Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
[TBL] [Abstract][Full Text] [Related]
8. [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
Endo S; Yamada T; Okuyama M; Hiraoka K; Konishi K; Kim C; Nakagawa T; Takeda K; Ueda Y; Matsumoto K; Nishikawa K; Nishijima J
Gan To Kagaku Ryoho; 2015 Mar; 42(3):359-61. PubMed ID: 25812508
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based targeted therapy for gastric cancer.
Lordick F; Peschel C; Siewert JR
Gastric Cancer; 2005; 8(4):206-8. PubMed ID: 16328593
[No Abstract] [Full Text] [Related]
12. Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.
Shitara K; Mizota A; Yatabe Y; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Jpn J Clin Oncol; 2011 May; 41(5):663-5. PubMed ID: 21335337
[TBL] [Abstract][Full Text] [Related]
13. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer.
Inui T; Asakawa A; Morita Y; Mizuno S; Natori T; Kawaguchi A; Murakami M; Hishikawa Y; Inui A
J Intern Med; 2006 Nov; 260(5):484-7. PubMed ID: 17040255
[No Abstract] [Full Text] [Related]
14. Trastuzumab for gastric cancer treatment.
Okines AF; Dewdney A; Chau I; Rao S; Cunningham D
Lancet; 2010 Nov; 376(9754):1736; author reply 1736-7. PubMed ID: 21093643
[No Abstract] [Full Text] [Related]
15. [A Case of HER2-Positive Unresectable Gastric Cancer with Multiple Lymph Node and Liver Metastases Controlled Effectively by Combination Chemotherapy with Capecitabine, Oxaliplatin, and Trastuzumab].
Sato N; Nakayama A; Takai Y; Kamata T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1266-1268. PubMed ID: 29394602
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report.
Al-Batran SE; Ruppert M; Jäger E
Onkologie; 2011; 34(1-2):42-5. PubMed ID: 21346384
[No Abstract] [Full Text] [Related]
17. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Weissinger F; Reymond M; Dumke K; Krüger M
Onkologie; 2011; 34(10):548-51. PubMed ID: 21985855
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab for gastric cancer treatment.
Fujita T
Lancet; 2010 Nov; 376(9754):1735; author reply 1735-6. PubMed ID: 21093641
[No Abstract] [Full Text] [Related]
19. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
20. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
Daum O; Skálová A; Rozkos T; Laco J
Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
